AI Drug Discovery Reaches the IPO Market

Iambic Therapeutics, backed by Coatue, Nvidia, Millennium, and Two Sigma, is bringing its AI-based drug development to public investors.

Stephen Taub September 23, 2026

Artificial intelligence and drug development are joining forces in one of the life sciences companies planning to go public soon.The venture capital arm of Tiger Cub Coatue Management and chip juggernaut Nvidia are among the major investors poised to benefit from the initial public offering

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2026 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.28.00 build:2026-09-14 Login